Research progress and clinical practice of radioligand therapy for prostate cancer

VernacularTitle:放射性配体疗法治疗前列腺癌的临床应用和研究进展
Author: Yachao LIU ¹ ; Shaoxi NIU ; Ruimin WANG ; Xu ZHANG
Author Information

1. 解放军总医院第一医学中心核医学科，北京　100853
Publication Type:Journal Article
Keywords: Radioligand therapy; Metastatic castration-resistant prostate cancer; 177Lu-PSMA-617; Prostate-specific membrane antigen
From: Chinese Journal of Urology 2025;46(8):622-631
CountryChina
Language:Chinese
Abstract: Metastatic castration-resistant prostate cancer（mCRPC）is the terminal stage of prostate cancer，often associated with poor prognosis and limited treatment options. Prostate-specific membrane antigen（PSMA），a type Ⅱ transmembrane glycoprotein，is highly expressed on the surface of most prostate cancer cells. The expression level of PSMA is significantly associated with tumor migration and invasion，making it a critical target in the diagnosis and treatment of prostate cancer. In recent years，radioligand therapy（RLT）targeting PSMA has rapidly advanced. 177Lu-PSMA-617 delivers beta radiation from 177Lu to selectively kill prostate cancer cells by inducing DNA damage. 177Lu-PSMA-617 has demonstrated promising efficacy and safety in mCRPC，gaining widespread endorsement in global prostate cancer guidelines. This review summarizes the mechanism，clinical evidence，and progress of RLT，with a focus on 177Lu-PSMA-617，offering insights for clinical practice and research.